Atossa Therapeutics (MEX:ATOS) Shiller PE Ratio: (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ATOS Atossa Therapeutics Inc MEX:ATOS
26 GF Score
Price MXN41.50
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Atossa Therapeutics  (MEX:ATOS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Atossa Therapeutics Shiller PE Ratio Related Terms


Atossa Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Atossa Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics Shiller PE Ratio Chart

Atossa Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Atossa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:ATOS vs SKYE, JSPR, TVRD: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Atossa Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atossa Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Shiller PE Ratio falls into.


MEX:ATOS
26GF Score
Atossa Therapeutics Inc MEX:ATOS
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Atossa Therapeutics's E10 for the quarter that ended in Mar. 2026 is calculated as:

For example, Atossa Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-20.016/330.2130*330.2130
=-20.016

Current CPI (Mar. 2026) = 330.2130.

Atossa Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201606 -2,230.325 241.018 -3,055.715
201609 243.628 241.428 333.222
201612 -2,671.974 241.432 -3,654.530
201703 -18,301.861 243.801 -24,788.711
201706 -2,093.201 244.955 -2,821.752
201709 -574.384 246.819 -768.454
201712 -221.402 246.524 -296.563
201803 -2,310.919 249.554 -3,057.837
201806 -1,497.292 251.989 -1,962.091
201809 -179.568 252.439 -234.891
201812 61.850 251.233 81.294
201903 -180.401 254.202 -234.344
201906 -230.507 256.143 -297.164
201909 -106.607 256.759 -137.105
201912 -73.554 256.974 -94.517
202003 -112.550 258.115 -143.988
202006 -148.880 257.797 -190.701
202009 -112.664 260.280 -142.935
202012 -262.574 260.474 -332.875
202103 -12.265 264.877 -15.290
202106 -17.915 271.696 -21.773
202109 -12.337 274.310 -14.851
202112 -12.308 278.802 -14.578
202203 -11.947 287.504 -13.722
202206 -15.901 296.311 -17.720
202209 -18.103 296.808 -20.140
202212 -17.546 296.797 -19.521
202303 -13.519 301.836 -14.790
202306 -20.573 305.109 -22.266
202309 -13.064 307.789 -14.016
202312 -15.277 306.746 -16.446
202403 -12.447 312.332 -13.160
202406 -13.740 314.175 -14.441
202409 -17.721 315.301 -18.559
202412 -16.476 315.605 -17.239
202503 -15.957 319.799 -16.477
202506 -19.771 322.561 -20.240
202509 -19.261 324.800 -19.582
202512 -24.128 324.054 -24.587
202603 -20.016 330.213 -20.016

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Atossa Therapeutics Business Description

Other Exchanges ATOS:USAYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score

Get the complete analysis for MEX:ATOS

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN41.50
Price